Brought to you by 
Lundbeck & Altana to mutually market CNS drugs in Germany
28 Feb 2001
Executive Summary
H. Lundbeck and Altana subsidiary Promonta have agreed to jointly market both companies' CNS products in Germany. As part of the agreement, Lundbeck is acquiring a 50% equity stake in Promonta.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Marketing (Licensing)
- Product or Technology Swap
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lundbeck & Altana to mutually market CNS drugs in Germany
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice